Key Publications
-
Chong, P.S.Y., Zhou, and Chng. W,J. (2019) Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia. Oncogene 38:1508-1519.
-
Zhou, J., Toh, S.H., and Chng, W.J. (2018) A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase. J Hematol Oncol. 11:36.
-
Thura, M., Al-Aidaroos, A.Q., Yong, W.P., Kono, K., Gupta, A., Lin, Y.B., and Zeng Q. (2016) PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight June 16;1(9):e87607.
-
Ye, Z., Al-aidaroos, A.Q.O., Park, J.E., Yuen, H.F., and Zeng, Q. (2015) PRL-3 activates mTORC1 in cancer progression. Scientific Reports, 5:17046 | DOI: 10.1038/srep17046.
Our innovative antibody drugs provide new hope to
hard-to-treat cancer patients.
CONTACT US
Top
